Testing nab-sirolimus for epithelioid hemangioendothelioma
Treatments studied
Part of Cancer clinical trials.
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have EHE that is growing or causing symptoms and needs treatment.
- You have at least one tumor that can be measured on a scan (like CT or MRI).
- You are 18 years or older.
- You are able to do daily activities with some help (ECOG 0–2).
- Your blood counts and organ function are within acceptable ranges.
- You must use effective birth control during and for a while after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of sirolimus (a targeted therapy) for people with a rare cancer called EHE that is growing or causing symptoms. If you have EHE that can't be removed with surgery and needs treatment, this study may be an option.
This study is tracking people with a rare blood vessel tumor called epithelioid hemangioendothelioma (EHE) to learn more about how it behaves and how best to care for you. By joining, you'll help doctors improve future treatments for this condition.
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
This study looks at different ways to stop taking sirolimus for children with KHE, a rare blood vessel tumor. It helps find the best plan to prevent the tumor from coming back after treatment.
This study tests whether a low dose or a high dose of sirolimus (a drug that stops abnormal cell growth) combined with prednisolone (a steroid) works better for children with a rare, aggressive vascular tumor called KHE that also causes low blood platelets (KMP). The goal is to find the safest and most effective dose to help shrink the tumor and improve blood counts.
This Phase 1 study tests different doses of nab-sirolimus to see if it is safe and how the body processes it. It is for people with advanced or metastatic solid tumors who also have moderate liver impairment.
Hear when a new Epithelioid Hemangioendothelioma (EHE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.